Given limited success from VEGF-targeting approaches and positive correlations between CD44 expression and enhanced angiogenic properties of cancer cells [50], the FKBPL peptide may prove advantageous in the field of novel anti-angiogenic agents currently in clinical use. The gene discussed is FKBPL; the disease is cancer.